

[412] BIOSIGHT LTD. IS DEVELOPING BST-236, A NOVEL ANTIMETABOLITE FOR FIRST-LINE TREATMENT OF HEMATOLOGICAL MALIGNANCIES AND DISORDERS

Ruth Ben Yakar, Biosight, Israel

- **Investment Rational**
Biosight Ltd. is a private Phase 2b stage biotech company, developing innovative oncology and hemato-oncology therapeutics, addressing large markets and unmet needs. Biosight has an experienced management team with strong and experienced investors.
- **Business Strategy**
Biosight intends to partner with global pharmaceutical companies to commercialize its products, including its lead product BST-236.
- **Core Technology**
Our lead product, BST-236, is a novel and distinctive antimetabolic agent, positioned to replace the backbone of oncology therapy, either as a single agent or in combination with targeted therapy.
- **Product Profile/Pipeline**
Our ongoing development programs focus on the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). A multi-center Phase 2b study for front-line single-agent treatment of AML patients unfit to receive standard therapy is ongoing, following a successful Phase 1/2, which demonstrated highly promising single-agent safety and efficacy in a most challenging population.
- **What's Next?**
The clinical data to date suggest that BST-236 may serve as a new therapeutic backbone for AML treatment. Additional clinical studies in high-risk MDS and a combination therapy in AML are planned for later this year. Moreover, the mechanism of action of BST-236, supported by experimental results, indicates a huge clinical and commercial potential across indications, including hematological and solid tumors.